Prognostic Value of the Endothelial Activation and Stress Index (EASIX) in Critically Ill Patients With Ischemic Stroke: A MIMIC-IV Database Analysis.
W, B., M, T., S, L., W, S., K, J., & L, T. (2026). Prognostic Value of the Endothelial Activation and Stress Index (EASIX) in Critically Ill Patients With Ischemic Stroke: A MIMIC-IV Database Analysis.. Brain and behavior. https://doi.org/10.1002/brb3.71708
W B, M T, S L, W S, K J, L T. Prognostic Value of the Endothelial Activation and Stress Index (EASIX) in Critically Ill Patients With Ischemic Stroke: A MIMIC-IV Database Analysis.. Brain and behavior. 2026; doi: 10.1002/brb3.71708
W B, M T, S L, et al. Prognostic Value of the Endothelial Activation and Stress Index (EASIX) in Critically Ill Patients With Ischemic Stroke: A MIMIC-IV Database Analysis.[J]. Brain and behavior. 2026. DOI: 10.1002/brb3.71708.
@article{w2026,
author = {Bai W and Tao M and Li S and Shi W and Jiang K and Tian L},
title = {Prognostic Value of the Endothelial Activation and Stress Index (EASIX) in Critically Ill Patients With Ischemic Stroke: A MIMIC-IV Database Analysis.},
journal = {Brain and behavior},
year = {2026},
doi = {10.1002/brb3.71708},
note = {PMID: 42625207},
}
TY - JOUR AU - Bai W AU - Tao M AU - Li S AU - Shi W AU - Jiang K AU - Tian L TI - Prognostic Value of the Endothelial Activation and Stress Index (EASIX) in Critically Ill Patients With Ischemic Stroke: A MIMIC-IV Database Analysis. T2 - Brain and behavior PY - 2026 DO - 10.1002/brb3.71708 AN - PMID:42625207 ER -
BACKGROUND: Systemic endothelial dysfunction is a critical driver of poor outcomes in ischemic stroke. We evaluated the prognostic value of the endothelial activation and stress index (EASIX) in critically ill stroke patients. METHODS: We analyzed 3063 patients with ischemic stroke from the MIMIC-IV database. The natural log-transformed EASIX (lnEASIX) was calculated from admission LDH, creatinine, and platelets. The primary outcome was designated as 28-day mortality, with secondary outcomes including in-hospital, 90-day, and 180-day mortality. Multivariable logistic and Cox proportional hazards regression, restricted cubic splines (RCS), and advanced clinical utility analyses (NRI, IDI, and decision curve analysis) were utilized. RESULTS: Evaluated as a continuous variable, a per-unit increase in lnEASIX was independently associated with an elevated risk for the primary endpoint of 28-day mortality (OR 1.47, 95% CI 1.36-1.59, p < 0.001), as well as all secondary mortality endpoints. RCS analysis confirmed a strictly linear, monotonic dose-response relationship (p for nonlinearity > 0.05). While lnEASIX demonstrated moderate standalone discrimination (AUC 0.64-0.67, comparable to SOFA), integrating it with the baseline SOFA score yielded significant incremental predictive value (NRI 0.208, IDI 0.011; both p < 0.01) and superior net clinical benefit. Subgroup analysis revealed consistent prognostic utility across most strata, though the impact was markedly more pronounced in patients without pre-existing cancer (p for interaction < 0.05). CONCLUSION: LnEASIX is a simple, robust, and continuous predictor of short- and long-term mortality in critically ill patients with ischemic stroke. Integrating this zero-cost biomarker with established intensive care scoring systems provides significant incremental value for early prognostic risk stratification.